Calliditas Therapeutics, STADA Submitted A Request To The European Medicines Agency To Convert Conditional Approval For Kinpeygo For Primary IgA Nephropathy To Standard Approval
Portfolio Pulse from Benzinga Newsdesk
STADA and Calliditas Therapeutics AB (NASDAQ:CALT) have submitted a request to the European Medicines Agency (EMA) to convert the conditional marketing authorization for Kinpeygo®, their treatment for primary IgA nephropathy (IgAN), to standard, or 'full', marketing authorization.
September 28, 2023 | 10:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Calliditas Therapeutics' request to the EMA for full marketing authorization for Kinpeygo® could potentially boost the company's market presence and revenues if approved.
The news directly pertains to Calliditas Therapeutics as they are seeking full marketing authorization for their product, Kinpeygo®. If approved, this could potentially increase the company's market presence and revenues, thus positively impacting the stock price in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100